Cyclo (Arg-Gly-Asp-D-Phe-Val) (TFA)

Cyclo (Arg-Gly-Asp-D-Phe-Val) (TFA) (Cyclo (RGDfV) (TFA) ) is an integrin αvβ3 inhibitor. Cyclo (Arg-Gly-Asp-D-Phe-Val) (TFA) has antitumor activity. Cyclo (Arg-Gly-Asp-D-Phe-Val) (TFA) can be used for the research of acute myeloid leukemia[1].

Product Specifications

CAS Number

[199807-33-5]

Product Name Alternative

Cyclo (RGDfV) (TFA) ; C (RGDfV) (TFA)

UNSPSC

12352209

Target

Apoptosis; Integrin

Type

Peptides

Related Pathways

Apoptosis; Cytoskeleton

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Cyclo_Arg-Gly-Asp-D-Phe-Val__TFA.html

Purity

99.40

Solubility

10 mM in DMSO

Smiles

O=C([C@@H](NC(CNC([C@H](CCCNC(N)=N)NC([C@H](C(C)C)NC1=O)=O)=O)=O)CC(O)=O)N[C@@H]1CC2=CC=CC=C2.FC(C(O)=O)(F)F

Molecular Formula

C28H39F3N8O9

Molecular Weight

688.65

References & Citations

[1]Shen ZH, et al. Targeting of the leukemia microenvironment by c (RGDfV) overcomes the resistance to chemotherapy in acute myeloid leukemia in biomimetic polystyrene scaffolds. Oncol Lett. 2016 Nov;12 (5) :3278-3284.